Vaccination with human papillomavirus-18 E1 protein plus α-galactosyl-ceramide induces CD8+ cytotoxic response and impairs the growth of E1-expressing tumors

Vaccine. 2019 Feb 21;37(9):1219-1228. doi: 10.1016/j.vaccine.2018.12.036. Epub 2019 Jan 28.

Abstract

CD8+ T cell-mediated immune response plays a major role in the clearance of virus-infected cells, including human papillomavirus (HPV). The effective treatment of women with normal cytology but persistent high risk-HPV infection or with low-grade intraepithelial lesions could take advantage of novel strategies based on vaccination with viral immunological targets with a wide spectrum of cross-protection. The helicase E1, expressed early during viral replication in HPV infection, is among the most conserved papillomavirus proteins, which makes it a good vaccine candidate. In the present study, we examined E1-specific CD8+ T cell and NK immune responses in a mouse model with α-galactosylceramide (α-GalCer) as an adjuvant. We found that mice immunized with E1 combined with α-GalCer elicited an E1-specific CD8+ T and NK cell cytotoxic responses, which correlated with growth inhibition of grafted melanoma B16-F0 cells expressing E1, both in prophylactic and therapeutic protocols.

Keywords: Cytotoxic CD8+ T cells; E1 protein; Human papillomavirus; NK cells; α-galactosylceramide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Animals
  • Cancer Vaccines / immunology*
  • Cytotoxicity, Immunologic*
  • Female
  • Galactosylceramides / administration & dosage*
  • Galactosylceramides / immunology
  • Human papillomavirus 18
  • Humans
  • Killer Cells, Natural / immunology
  • Melanoma, Experimental / prevention & control
  • Melanoma, Experimental / therapy
  • Melanoma, Experimental / virology
  • Mice
  • Mice, Inbred C57BL
  • Oncogene Proteins, Viral / administration & dosage
  • Oncogene Proteins, Viral / immunology*
  • Papillomavirus Infections / immunology
  • Papillomavirus Infections / prevention & control
  • Papillomavirus Infections / therapy
  • T-Lymphocytes, Cytotoxic / immunology*
  • Transplants
  • Tumor Cells, Cultured / immunology
  • Vaccination

Substances

  • Adjuvants, Immunologic
  • Cancer Vaccines
  • Galactosylceramides
  • Oncogene Proteins, Viral
  • alpha-galactosylceramide
  • oncogene protein E1, Human papillomavirus type 18